After William Blair and H.C. Wainwright gave Collegium Pharmaceutical (NASDAQ: COLL) a Buy rating last month, the company received another Buy, this time from Cantor Fitzgerald. Analyst Brandon Folkes maintained a Buy rating on Collegium Pharmaceutical today and set a price target of $35. The company’s shares closed yesterday at $15.25, close to its 52-week low of $13.70.
Folkes wrote:
“We expect upwards earnings revisions to levels not reflected in FactSet consensus to drive COLL shares higher. Valuation Summary We use a blend of DCF and EV/EBITDA to arrive at our $35 price target. The Disclosure Section may be found on pages 5 – 6.Valuation We use a blend of DCF and EV/EBITDA to arrive at our $35 price target.”
According to TipRanks.com, Folkes ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -5.8% and a 24.3% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Opiant Pharmaceuticals Inc, Eagle Pharmaceuticals Inc, and ANI Pharmaceuticals Inc.
Currently, the analyst consensus on Collegium Pharmaceutical is a Strong Buy with an average price target of $32.75, an 114.8% upside from current levels. In a report issued on January 10, H.C. Wainwright also maintained a Buy rating on the stock with a $32 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $29.90 and a one-year low of $13.70. Currently, Collegium Pharmaceutical has an average volume of 452.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Collegium Pharmaceutical, Inc. operates as a pharmaceutical company, which engages in the developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta® ER and Nucynta.
